Below are the most recent publications written about "Molecular Mimicry" by people in Profiles.
-
Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013 Oct; 26(4):792-821.
-
Talbott VA, Yeo CJ, Brody JR, Witkiewicz AK. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. J Surg Res. 2012 Jul; 176(1):154-8.
-
Krishna OD, Kiick KL. Supramolecular assembly of electrostatically stabilized, hydroxyproline-lacking collagen-mimetic peptides. Biomacromolecules. 2009 Sep 14; 10(9):2626-31.
-
Tamamura H, Tanaka T, Tsutsumi H, Ohashi N, Hiramatsu K, Araki T, Ojida A, Hamachi I, Wang Z, Peiper SC, Trent JO, Ueda S, Oishi S, Fujii N. Development of chemokine receptor CXCR4 antagonists using bio-mimetic strategy. Adv Exp Med Biol. 2009; 611:145-6.
-
Delevoye C, Nilges M, Dehoux P, Paumet F, Perrinet S, Dautry-Varsat A, Subtil A. SNARE protein mimicry by an intracellular bacterium. PLoS Pathog. 2008 Mar; 4(3):e1000022.
-
Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008 Jun; 49(6):1344-52.
-
Kim SH, Kiick KL. Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors. Peptides. 2007 Nov; 28(11):2125-36.
-
Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006 Oct; 112(1):57-70.
-
Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol. 2005 Dec; 169(1-2):31-8.
-
Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, Trent JO, Nakashima H, Yamamoto N, Peiper SC, Otaka A, Fujii N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem. 2005 May 5; 48(9):3280-9.